araag2/HINT huggingface dataset:
Clinical trial NCT00140452 (phase 2, status: completed)
Conditions: amyotrophic lateral sclerosis, als
ICD codes: G12.21
Drugs: thalidomide
SMILES: CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Clinically proven ALS

          -  Disease duration less than or equal to 5 years

          -  ALSFRS-R score equal to or greater then 30

        Exclusion Criteria:

          -  Patients with known deep venous thrombosis or hyper coagulable state will be excluded

          -  Patients with FVC less than 80%
Clinical trial NCT00457821 (phase 2, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: ivacaftor 25 mg/75 mg, ivacaftor 75 mg/150 mg, ivacaftor 150 mg or 250 mg, placebo
SMILES: CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C, CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C, CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Weighing at least 40 kg

          -  Confirmed diagnosis of cystic fibrosis (CF) and G551D mutation in at least 1 allele

          -  Forced expiratory volume in 1 second (FEV1) of at least 40% of predicted normal for
             age, gender, and height

          -  Willing to remain on stable medication regimen for the duration of study participation

          -  No significant clinical laboratory abnormalities, not pregnant, and willing to use at
             least 2 highly effective birth control methods during Part 1 and 1 highly effective
             birth control method during Part 2 of the study

          -  No clinically significant abnormalities that would have interfered with the study
             assessments, as judged by the investigator

        Exclusion Criteria:

          -  History of any illness or condition that might confound the results of the study or
             pose an additional risk in administering study drug to the subject

          -  Ongoing acute respiratory infection, pulmonary exacerbation, or changes in therapy for
             pulmonary disease within 14 days of Day 1 of the study

          -  History of alcohol, medication or illicit drug abuse within one year prior to Day 1

          -  Abnormal liver function ≥ 3x the upper limit of normal

          -  History of abnormal renal function (creatinine clearance < 50 mL/min using
             Cockcroft-Gault equation)

          -  History of solid organ or hematological transplantation

          -  Pregnant or breast-feeding (for women)

          -  Ongoing participation in another therapeutic clinical trial, or prior participation in
             an investigational drug study without appropriate washout

          -  Concomitant use of any inhibitors or inducers of cytochrome P450 3A4 (CYP3A4)
Clinical trial NCT00147121 (phase 2/phase 3, status: completed)
Conditions: lymphoma, b-cell
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: rituximab + standard chop, rituximab + bi-weekly chop
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          1. Histological confirmed, low-grade B-cell lymphoma except mantle cell lymphoma and
             histologic transformation to DLBCL

          2. CD20-positive

          3. Ann Arbor CS III or IV

          4. Lymphoma cell count in PB≦10,000/mm3

          5. 20<=age<=69

          6. ECOG PS 0-2

          7. Bidimensionally measurable disease >1.5cm in a single dimension by CT scans

          8. No prior chemotherapy, radiotherapy, interferon-alfa, or antibody therapy

          9. Normal BM, hepatic, renal, cardiac, and pulmonary function

         10. Written informed consent

        Exclusion Criteria:

          1. CNS involvement

          2. Glaucoma

          3. DM treated by insulin

          4. Uncontrollable HT

          5. AP, AMI

          6. Positive HBs antigen

          7. seropositive to HCV

          8. seropositive to HIV

          9. Interstitial pneumonitis, pulmonary fibrosis, or emphysema

         10. Severe infection

         11. Liver cirrhosis

         12. Double cancer

         13. Pregnant or lactating

         14. Patients who desire auto PBST after CR

         15. Patients treated with major tranquilizer or antidepressant
Clinical trial NCT00443287 (phase 2, status: completed)
Conditions: intermittent claudication
ICD codes: I70.211, I70.212, I70.213, I70.218, I70.219, I70.611, I70.612
Drugs: ataciguat (hmr1766), placebo, cilostazol
SMILES: ClC1=CC=C(S1)S(=O)(=O)NC1=C(C=C(Cl)C=C1)C(=O)NC1=CC=C(C=C1)S(=O)(=O)N1CCOCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Patient with stable symptoms of intermittent claudication of the lower extremities,
             secondary to chronic occlusive arterial disease from atherosclerosis etiology
             (symptoms present for 6 months or longer and not significantly changed within the past
             3 months)

          -  Initial claudication distance of 30 to 250 meters at screening constant workload
             treadmill test

          -  Confirmation of underlying Peripheral Arterial Disease (PAD) at screening

          -  Confirmation of symptom stability at randomization based on constant workload
             treadmill test performance

          -  The patient must have optimal cardiovascular risk prevention and appropriate
             management of PAD, including clopidogrel at the dose of 75mg per day, during the study
             period

        Exclusion Criteria:

          -  Patient participated in investigational clinical trials in the last month prior to
             screening

          -  Pregnant or breast-feeding woman or woman without documented double birth control
             measures for at least 3 months prior to randomization

          -  Symptoms of PAD before the age of 40 years

          -  Recent initiations or discontinuation of treatment by vasoactive agents (e.g.,
             pentoxifylline, berprost sodium, papverine, isoxsuprine, nylidrin, cyclandelate, and
             niacin derivatives). Patients treated by cilostazol within 3 months prior to screening
             will also be excluded

          -  Recent lower-extremity surgical or endovascular arterial reconstructions or
             sympathectomy, or recent deep venous thrombosis

          -  Recent occurrence of at least one of the following: acute myocardial infarction,
             unstable angina, coronary artery bypass graft, percutaenous coronary intervention,
             transient ischemic attack or stroke

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00630344 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: rad001, bicalutamide
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC, [H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age or older

          -  Histologically documented prostate cancer

          -  Castration resistant prostate cancer defined as two rising PSAs on castration therapy

          -  Baseline PSA of 2ns/mL or greater

          -  Testosterone of 50ng/mL or less

          -  Patients on LHRH agonist/antagonist must continue therapy at the recommended dosing
             intervals

          -  Prior bicalutamide is allowed as long as treatment was for 6 months or longer

          -  Metastatic disease is not required

          -  Minimum of four weeks since any major surgery, completion of radiation, or completion
             of all prior systemic anticancer therapy

          -  ECOG Performance Status equal to or less than 2

          -  Adequate bone marrow and liver function as outlined by parameters in the protocol

        Exclusion Criteria:

          -  Prior treatment with any investigational drug within the preceding 4 weeks

          -  Prior treatment with an mTOR inhibitor

          -  Fasting lipids over the parameters outlined in the protocol

          -  Chronic treatment with systemic steroids or another immunosuppressive agent

          -  Patients should not receive immunization with attenuated live vaccines during study
             period or within one week of study entry

          -  Uncontrolled brain or leptomeningeal metastases, including patients who continue to
             require glucocorticoids for brain or leptomeningeal metastases

          -  Other malignancies within the past 3 years except for adequately treated or basal
             squamous cell carcinomas of the skin

          -  Patients who have any severe and/or uncontrolled medical conditions or other
             conditions that could affect their participation in the study

          -  Known history of HIV seropositivity

          -  Impairment of gastrointestinal function or gastrointestinal disease that may
             significantly alter the absorption of RAD001

          -  Patients with an active, bleeding diathesis or on oral anti-vitamin K medication
             (except low dose coumarin)

          -  Men able to conceive and unwilling to practice an effective method of birth control

          -  Known hypersensitivity to RAD001 or other rapamycins or to its excipients

          -  History of noncompliance to medical regimens
Clinical trial NCT00266253 (phase 2, status: completed)
Conditions: diabetes mellitus type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: gk activator (2), metformin
SMILES: CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients 30-75 years of age;

          -  type 2 diabetes mellitus;

          -  individual maximal tolerated daily dose of metformin monotherapy for >=3 months prior
             to screening.

        Exclusion Criteria:

          -  type 1 diabetes mellitus;

          -  any oral anti-hyperglycemic medication, other than metformin monotherapy, during last
             3 months
Clinical trial NCT01324999 (phase 2/phase 3, status: completed)
Conditions: pulmonary hypertension
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: tadalafil
SMILES: [H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Biopsy proven sarcoidosis

          -  Mean pulmonary artery pressure > 25 mmHg at rest or greater than 30 mmHg with exercise
             by right heart catheterization within 1 year prior to entry into study

          -  Pulmonary capillary wedge pressure ≤ 15 mmHg

          -  PVR values ≥ 3.0 Woods units

          -  Forced vital capacity (FVC) > 40% predicted

          -  Forced expiratory volume in 1 second (FEV1) > 40% predicted

          -  WHO functional class II or III

          -  Stable sarcoidosis treatment regimen for three months prior to entry into study

          -  6 minute walk distance between 150-450 meters

          -  Stable dose of antihypertensive medications

          -  On no other medication to treat PAH (sildenafil, vardenafil, treprostinil,
             epoprostenol, iloprost, bosentan, ambrisentan) within one month prior to enrollment
             and during duration of the study

          -  Non-pregnant females

        Exclusion Criteria:

          -  Exercise limitation related to a non-cardiopulmonary reason (e.g. arthritis)

          -  Severe systemic hypertension > 170/95

          -  Severe systemic hypotension < 90/50

          -  History of priapism

          -  Patients with congestive heart failure (left ventricular dysfunction) LVEF < 45% by
             echocardiogram

          -  Anticipation by the investigator for escalation in sarcoidosis treatment during the
             course of the study

          -  Pulmonary hypertension related to etiology other than sarcoidosis (i.e. HIV,
             scleroderma, chronic thromboemboli)

          -  Use within 1 month of an sildenafil or vardenafil

          -  WHO functional class IV status

          -  Patients with severe other organ disease felt by investigators to impact on survival
             during the course of the study

          -  Subjects with liver function abnormalities (ALT or AST > 3 times the upper limit of
             normal at screening or at baseline) or chronic liver disease

          -  Advanced kidney failure (GFR < 30 ml/min at screening or at baseline)

          -  History of hypersensitivity reaction or adverse effect related to tadalafil

          -  Pregnant or lactating women

          -  Concomitant use of nitrates (any form) either regularly or intermittently

          -  Concomitant use of potent CYP3A inhibitors (eg, ritonavir, ketoconazole, itraconazole)

          -  Any additional contraindications and precautions specified in the package inserts for
             Tadalafil (Adcirca) not listed above
Clinical trial NCT00715689 (phase 2, status: completed)
Conditions: growth hormone disorder, adult growth hormone deficiency
ICD codes: F20.81, F21, F34.0, F34.1, F42.3, F45.0, F51.5, D81.810, E53.0, E53.1, E61.0, E61.1, E61.2, E61.3
Drugs: nnc126-0083, nnc126-0083, nnc126-0083, nnc126-0083, placebo, placebo, placebo, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  GHDA subjects as defined in the Consensus guidelines for the diagnosis and treatment
             of adults with GH deficiency II

          -  Fertile females must agree to use appropriate contraceptive methods and have a
             negative pregnancy test at inclusion

          -  GH replacement therapy for more than 3 months

          -  Body Mass Index (BMI, kg/m2) of 22.0 to 35.0 kg/m2, both inclusive

        Exclusion Criteria:

          -  Females of childbearing potential who are pregnant, breast-feeding or intend to become
             pregnant or are not using adequate contraceptive methods

          -  Malignant disease

          -  Proliferative retinopathy judged by retina-photo within the last year - only with
             concomitant diabetes

          -  Heart insufficiency, NYHA class greater than 2

          -  Subjects with diabetes with an HbA1C above 8.0%

          -  Diabetic receiving insulin treatment

          -  Stable pituitary replacement therapy for less than 3 months

          -  Impaired liver function

          -  Impaired kidney function
Clinical trial NCT01127503 (phase 2, status: terminated)
Conditions: velo-cardio-facial syndrome, psychosis
ICD codes: F53.1, F29
Drugs: metyrosine, placebo
SMILES: C[C@](N)(CC1=CC=C(O)C=C1)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    enrollment, study-design and execution challenges.
  
Eligibility criteria:

        Key Inclusion Criteria:

          1. Females of childbearing potential cannot be at risk of pregnancy during the study.

          2. Genetically confirmed diagnosis of VCFS at the time of screening.

          3. Must have one of the following Diagnostic and Statistical Manual of Mental Disorders,
             Fourth Edition Text Revision (DSM-IV TR) diagnoses (applicable based upon clinical
             assessments): schizophrenia, schizoaffective disorder, psychosis not otherwise
             specified (NOS), bipolar disorder, or mood disorder with psychotic features.

          4. A total PANSS composite score >65.

          5. Willing to discontinue psychotropic medications. -

        Key Exclusion Criteria:

          1. Evidence of acute suicidality.

          2. Known or observed clinically significant cardiovascular, pulmonary, renal, hepatic, or
             gastrointestinal disorders; other clinically significant psychiatric/neurological and
             sleep disorders by DSM-IV-TR criteria; endocrine, or hematological or metabolic
             diseases.

          3. Full scale IQ of less than 50.

          4. Pregnancy.

          5. Not using a reliable means of contraception.

          6. Systolic blood pressure of ≤110 mm/Hg or ≥160 mm/Hg, diastolic blood pressure ≤60
             mm/Hg or ≥90 mm/Hg, or has clinically symptomatic orthostatic changes.

          7. QTcF > 450 msec, or PR > 250 msec, or QRS > 110 msec on ECG.

          8. History of seizure disorder. -
Clinical trial NCT00448097 (phase 2, status: terminated)
Conditions: prostatic neoplasms
ICD codes: B38.81, N42.31, Z87.430, N40.0, N40.1
Drugs: cetuximab, docetaxel
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    lack of patient population - slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic proof of prostatic adenocarcinoma without evidence of regional and/or
             distant metastasis, clinical stage T1c or T2a with high grade disease (Gleason's 8-10)
             on initial biopsy, or clinical stage T2b-T2c with Gleason's grade 7 or above with a
             PSA ≥ 10ng/ml, or clinical stage T3.

          -  Recent (< 6 weeks prior to study entry) negative bone scan and MRI of abdomen and
             pelvis.

          -  Appropriate surgical candidate for radical prostatectomy and a performance status of <
             2 (Zubrod scale).

          -  Patients should have adequate bone marrow function defined as an absolute peripheral
             granulocyte count > 1,500 and platelet count of > 100,000, adequate hepatic function
             with a bilirubin < 1.5 mg % and SGPT < 2.5x the upper limits of normal, adequate renal
             function defined as serum creatinine < 1.5 x ULN.

          -  Patients must have normal coagulation profile (PT, PTT) and no history of substantial
             non-iatrogenic bleeding diatheses. Use of anticoagulants is limited to local use only
             (for control of central line patency).

          -  Patients must have no history of congestive heart failure or previous MI within the
             last 12 months.

        Exclusion Criteria:

          -  Previous or current hormonal treatment, chemotherapy, radiation therapy, immunotherapy
             or other investigational status drug.

          -  Unable to tolerate transrectal ultrasound.

          -  Patients who are not appropriate surgical candidates for radical prostatectomy based
             on the evaluation of co-existent medical diseases and competing causes of death.
             Patients with uncontrolled cardiac, hepatic, renal or neurologic/psychiatric disorder
             are not eligible. Patients with uncontrolled and symptomatic orthostatic hypotension
             or uncontrolled hypertension are not eligible.

          -  Patients who are HIV positive or have chronic hepatitis B or C infections are not
             eligible.

          -  Patients on oral steroid medications are not eligible.

          -  Patients with significant arteriosclerotic disease, as defined by a previous arterial
             bypass claudication limiting activity, or a history of cerebrovascular events within
             the last year (including TIA) are not eligible.

          -  Prior severe infusion reaction to a monoclonal antibody.
Clinical trial NCT00083473 (phase 2, status: terminated)
Conditions: leukemia, lymphocytic, chronic, lymphoma, small lymphocytic
ICD codes: C91.11, C91.12, C91.10, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: pivanex
SMILES: CCCC(=O)OCOC(=O)C(C)(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have a confirmed diagnosis of CLL or small lymphocytic lymphoma (SLL)
             based upon the Revised NCI-sponsored Working Group guidelines for CLL;

          -  Relapsed or refractory disease after previous chemotherapy treatment;

          -  Age > 18 years;

          -  Adequate renal function with creatinine <= 1.5 mg/dL;

          -  Adequate liver function with alkaline phosphatase <= 2.5 X upper limit of normal,
             serum glutamic oxaloacetic transaminase (SGOT), and serum glutamic pyruvic
             transaminase (SGPT) <= 2.5 X upper limit of normal; and total bilirubin <= 2.0 X upper
             limit of normal;

          -  Adequate bone marrow function as determined by having platelets > 50,000/mm3 without
             transfusion in the preceding 2 weeks and an absolute neutrophil count (ANC) => 1,500
             cells/mm3 without growth factor support; unless cytopenias due to marrow infiltration;

          -  Able to give informed consent;

          -  A minimum of 4 weeks must have elapsed from the completion of any previous treatment
             regimen, including radiation and biologic therapies (6 weeks if a prior nitrosourea or
             mitomycin C, 12 weeks if radioimmunotherapy) to treatment on Day 1 Cycle 1. Patients
             must have recovery from treatment-associated toxicity(ies);

          -  A predicted life expectancy of at least 6 months; and

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

        Exclusion Criteria:

          -  More than three systemic treatment regimens for CLL/SLL (excluding immunotherapies and
             biologic therapies);

          -  Concurrent malignancy that the patient has not been free of for at least 5 years,
             excluding curatively treated carcinoma-in-situ or non-melanoma skin cancer;

          -  Any pregnant or lactating females. Females of childbearing potential must have a
             negative pregnancy test and all male and female patients of reproductive potential
             must agree to use adequate birth control;

          -  Known HIV-positive patients;

          -  Any underlying medical conditions or circumstances that would contraindicate therapy
             with study treatment, affect compliance or impair evaluation of study endpoints;

          -  Receiving investigational agents within 4 weeks of the study treatment; and

          -  Known allergy to reagents in the study.
Clinical trial NCT01164579 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: tasocitinib plus methotrexate, tofacitinib plus placebo methotrexate, placebo tofacitinib plus methotrexate
SMILES: [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients with moderate to severe early rheumatoid arthritis (< 2 years) who are
             methotrexate and biologic disease modifying antirheumatic drug naive.

        Exclusion Criteria:

          -  Pregnant or lactating patients;

          -  Patients with renal or hepatic impairment or other severe or progressing disease;

          -  Patients with contraindication to magnetic resonance imaging with gadolinium contrast.